Givastomig - I-MAB Biopharma
Alternative Names: ABL-111; CD4B; Giva; TJ-033721; TJ-CD4B; TJ-CLDN4BLatest Information Update: 10 Jul 2025
At a glance
- Originator I-MAB Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Adenocarcinoma; Gastric cancer; Pancreatic cancer; Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 10 Jul 2025 Givastomig licensed to Handok Inc in South Korea prior to July 2025 (Handok Inc pipeline, July 2025)
- 02 Jul 2025 Updated efficacy and adverse events data from a phase Ib trial in Solid tumours released by I-Mab Biopharma
- 30 Jun 2025 Updated efficacy data from a phase Ib trial in Solid tumours released by I-Mab Biopharma